Artiva Biotherapeutics (ARTV) News Today $2.88 +0.11 (+3.97%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$2.88 +0.00 (+0.17%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ARTV Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) CEO Sells $69,615.00 in StockAugust 20, 2025 | marketbeat.comCantor Fitzgerald Issues Negative Forecast for ARTV EarningsAugust 12, 2025 | marketbeat.comArtiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Average Recommendation of "Buy" from AnalystsAugust 12, 2025 | marketbeat.comHC Wainwright Issues Pessimistic Estimate for ARTV EarningsAugust 11, 2025 | marketbeat.comWedbush Analysts Raise Earnings Estimates for ARTVAugust 11, 2025 | marketbeat.comArtiva (ARTV) Q2 Loss Widens 19.7%August 6, 2025 | fool.comArtiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business HighlightsAugust 6, 2025 | globenewswire.comArtiva Biotherapeutics (ARTV) to Release Earnings on ThursdayJuly 31, 2025 | marketbeat.comArtiva Biotherapeutics (NASDAQ:ARTV) Stock Price Up 8.8% - Still a Buy?July 18, 2025 | marketbeat.comArtiva Biotherapeutics, Inc. (NASDAQ:ARTV) Given Consensus Rating of "Buy" by BrokeragesJuly 18, 2025 | marketbeat.comArtiva Biotherapeutics Rings the Closing BellJuly 14, 2025 | nasdaq.comWill Artiva Biotherapeutics (NASDAQ:ARTV) Spend Its Cash Wisely?June 29, 2025 | finance.yahoo.comArtiva Biotherapeutics Approves Equity Plan AmendmentJune 25, 2025 | tipranks.comARTV - Artiva Biotherapeutics Inc Key Metrics - MorningstarJune 24, 2025 | morningstar.comMResearch Analysts Offer Predictions for ARTV FY2026 EarningsJune 11, 2025 | marketbeat.comHC Wainwright Reiterates "Buy" Rating for Artiva Biotherapeutics (NASDAQ:ARTV)June 11, 2025 | marketbeat.comArtiva Biotherapeutics to Participate in the Jefferies Global Healthcare ConferenceMay 28, 2025 | globenewswire.comLatest Artiva Biotherapeutics Stock News | NASDAQ:ARTV | BenzingaMay 22, 2025 | benzinga.comTD Cowen Keeps Their Buy Rating on Artiva Biotherapeutics, Inc. (ARTV)May 16, 2025 | theglobeandmail.comNeedham Remains a Buy on Artiva Biotherapeutics, Inc. (ARTV)May 16, 2025 | theglobeandmail.comResearch Analysts Issue Forecasts for ARTV FY2025 EarningsMay 16, 2025 | marketbeat.comArtiva reports promising AlloNK therapy results in B-NHL studyMay 15, 2025 | investing.comArtiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual MeetingMay 13, 2025 | globenewswire.comQ1 Earnings Estimate for ARTV Issued By WedbushMay 13, 2025 | marketbeat.comArtiva Biotherapeutics (NASDAQ:ARTV) Releases Quarterly Earnings Results, Misses Expectations By $0.15 EPSMay 12, 2025 | marketbeat.comArtiva Biotherapeutics Reports Q1 2025 ProgressMay 10, 2025 | tipranks.comArtiva Biotherapeutics: Strategic Delay and Expanded Research Justify Buy RatingMay 8, 2025 | tipranks.comArtiva Biotherapeutics, Inc.: Strategic Advancements and Market Potential in Biotherapeutics Highlighted by Phase IIa Trial Initiation and FDA ClearanceMay 8, 2025 | tipranks.comArtiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business HighlightsMay 8, 2025 | globenewswire.comArtiva Biotherapeutics, Inc. (NASDAQ:ARTV) Given Consensus Recommendation of "Buy" by BrokeragesMay 6, 2025 | marketbeat.comArtiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual MeetingApril 28, 2025 | globenewswire.comArtiva Biotherapeutics (NASDAQ:ARTV) Earns "Buy" Rating from Needham & Company LLCApril 10, 2025 | marketbeat.comArtiva CMO Thorsten Graef switches to advisor role, Subhashis Banerjee succeedsApril 8, 2025 | markets.businessinsider.comArtiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical OfficerApril 8, 2025 | globenewswire.comArtiva Biotherapeutics Reports 2024 Financial ResultsApril 1, 2025 | tipranks.comArtiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare ConferenceMarch 31, 2025 | globenewswire.comEquities Analysts Set Expectations for ARTV Q1 EarningsMarch 29, 2025 | marketbeat.comArtiva Biotherapeutics stock rises following analyst optimismMarch 28, 2025 | uk.investing.comBrokers Offer Predictions for ARTV FY2025 EarningsMarch 28, 2025 | marketbeat.comAnalysts Issue Forecasts for ARTV Q1 EarningsMarch 28, 2025 | marketbeat.comCantor Fitzgerald Sticks to Their Buy Rating for Artiva Biotherapeutics, Inc. (ARTV)March 27, 2025 | markets.businessinsider.comArtiva Biotherapeutics price target lowered to $20 from $23 at Cantor FitzgeraldMarch 27, 2025 | markets.businessinsider.comHC Wainwright Reaffirms Buy Rating for Artiva Biotherapeutics (NASDAQ:ARTV)March 27, 2025 | marketbeat.comArtiva Biotherapeutics (NASDAQ:ARTV) Price Target Cut to $20.00 by Analysts at Cantor FitzgeraldMarch 26, 2025 | marketbeat.comArtiva Biotherapeutics (NASDAQ:ARTV) Earns Outperform Rating from WedbushMarch 26, 2025 | marketbeat.comArtiva Biotherapeutics' (ARTV) "Buy" Rating Reaffirmed at Needham & Company LLCMarch 26, 2025 | marketbeat.comArtiva Biotherapeutics Reports Full Year 2024 Results and Updates on AlloNK® Autoimmune Program with Key Leadership StrengtheningMarch 26, 2025 | nasdaq.comArtiva Biotherapeutics, Inc. (ARTV) Gets a Buy from TD CowenMarch 25, 2025 | markets.businessinsider.comArtiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business HighlightsMarch 24, 2025 | globenewswire.comArtiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Consensus Recommendation of "Buy" from BrokeragesMarch 15, 2025 | marketbeat.com Get Artiva Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARTV and its competitors with MarketBeat's FREE daily newsletter. Email Address ARTV Media Mentions By Week ARTV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARTV News Sentiment▼-0.120.71▲Average Medical News Sentiment ARTV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARTV Articles This Week▼21▲ARTV Articles Average Week Get Artiva Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARTV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ANNX News NMRA News VOR News ALMS News IMMP News TKNO News SCPH News ALLO News SGMT News SOPH News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARTV) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artiva Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artiva Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access